Lifeward shares surge 18.37% premarket after strategic transaction with Oramed secures POD™ technology transfer and $47M funding.

Lifeward Ltd. surged 18.37% in premarket trading following the announcement of a strategic transaction with Oramed Pharmaceuticals, which involves transferring Oramed’s proprietary POD™ oral drug delivery platform to Lifeward in exchange for a 49.9% beneficial ownership stake. Oramed will also invest $18 million through senior secured convertible notes with 100% warrant coverage and manage the clinical trial for the technology. The deal positions Lifeward to leverage Oramed’s biotech innovation while retaining its revenue-generating medical robotics portfolio, including FDA-approved ReWalk and AlterG products. Oramed will receive 4% of ReWalk’s net sales for up to 10 years, and Lifeward’s CEO, Mark Grant, emphasized the transaction’s potential to accelerate profitability and diversify the company’s biomedical portfolio. The transaction, contingent on shareholder approval and milestone achievements, underscores a strategic alignment of both companies’ growth ambitions in medical technology and biopharma.